CJC-1295/Ipa
People mainly take CJC-1295/Ipa for energy, recovery, skin & hair. Based on 2 first-hand reports. Ranked #1682 of 1,974 overall.
5
User score
Not enough data0% positive0% mixed0% negative100% unclear
Of reports that state an outcome, 0% are positive.
Clinical research
Research pending
High-risk compound. Peptides are not approved as supplements, carry serious and sometimes irreversible risks, are banned in competitive sport and may be restricted where you live. Nothing here is a recommendation to use it.
What CJC-1295/Ipa does, according to users
Of the people who reported each effect, the share who said it got better.
betterno changeworse
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
Research data for CJC-1295/Ipa is being compiled.
Dosage people report
As stated by users — not a recommendation. Follow the label or your doctor.
No doses stated in the reports so far.
Reported side effects
How often each side effect came up across all reports.
No side effects reported so far.
What users say
Verbatim quotes, shortened only — each links to the original discussion.
“cjc/ipa, recovery, better skin, anti aging”
“ran things like CJC with Ipa...recovery and energy instead of just scale”
Other options for energy
Retatrutide
Peptide · 298 reports
74% report better energy
Mostly positiveBResearch: Moderate
Caffeine + L-Theanine
Supplement · 46 reports
80% report better energy
Mostly positive
Tirzepatide
Medication · 219 reports
56% report better energy
Mostly positiveAResearch: Strong
Creatine Monohydrate
Supplement · 139 reports
97% report better energy
Mostly positiveAResearch: Strong
Magnesium Malate
Supplement · 103 reports
95% report better energy
Mostly positiveDResearch: None
Semaglutide
Medication · 137 reports
53% report better energy
Mostly positiveAResearch: Strong
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 2, 2026. How we rate